Sorrento Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniafounded In 2006The Company Focuses On Developing Innovative Therapies For Cancerautoimmune Disordersinflammationviral Infectionsand Neurodegenerative Diseasessorrento Utilizes Its Proprietary G Maba C Antibody Library And Various Targeted Delivery Platforms To Create Next Generation Treatments The Companyae S Product Pipeline Includes A Range Of Therapies For Pain Managementsuch As Resiniferatoxinrtxfor Chronic Pain And Semdexaa Ca Corticosteroid Formulation For Sciaticasorrento Is Also Active In Developing Solutions For Covid 19Including Antiviralscell Therapiesvaccinesand Diagnosticstheir Advanced Technologies Include Car T Dar Ta C Therapiesantibody Drug Conjugatesand Oncolytic Virusesall Aimed At Precision Treatment And Enhanced Therapeutic Delivery Led By Ceo Henry Hjiphdsorrento Is Committed To Addressing Unmet Medical Needs And Advancing Its Clinical Candidatesthe Company Is Publicly Traded As Srne On Otc Markets And Engages In Partnerships To Enhance Its Research And Development Efforts
